Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the evidence-base for the use of ketamine to treat trauma-related mental health conditions, and whether they plan to provide such treatments through NHS mental health services.

Ketamine does not have a marketing authorisation in the United Kingdom for use in the treatment of any mental health conditions. Esketamine nasal spray, an isomer of ketamine, is licensed for treatment-resistant depression that has not responded to at least two different antidepressants in the current moderate to severe depressive episode in adults, and for the treatment of adults with a moderate to severe episode of major depressive disorder, as acute short-term treatment for the rapid reduction of depressive symptoms, which, according to clinical judgement, constitutes a psychiatric emergency.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new, licenced medicines represent a clinically and cost-effective use of resources.

The NICE has been unable to recommend esketamine for treatment-resistant depression due to uncertainties in its clinical and cost-effectiveness. It is not therefore routinely funded by the NHS in England for any indication.

The NICE was unable to make recommendations on the use of esketamine nasal spray for the treatment of major depressive disorder because the marketing authorisation holder did not provide an evidence submission.